drugset / Trial / NCT05385185
Clinical Observation of ICI Combined With Recombinant Human Endostatin on Leptomeningeal Metastasis of Lung Cancer
NaSingle-groupOpen-labelTreatment
Summary
immune checkpoint inhibitor combined with recombinant human endostatin can improve the 3-month OS rate of leptomeningeal metastasis of lung cancer, and the combination is safe
Timeline
- Start
- 2022-05-01
- Primary completion
- 2024-05-03
- Completion
- 2024-12-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Camrelizumab | Monoclonal antibody | 200 mg | Intravenous |
| Subject | Envafolimab | Monoclonal antibody | 150 mg | Subcutaneous |
| Subject | Recombinant human vascular endostatin | Protein / enzyme biologic | 30 mg | Intravenous |